|
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
RECRUITINGPhase 4Sponsored by Takeshi Morimoto
Actively Recruiting
PhasePhase 4
SponsorTakeshi Morimoto
Started2022-06-14
Est. completion2030-03
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05347069
Summary
The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.
Eligibility
Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria: * Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization * Patients for whom consent can be obtained Exclusion Criteria: * Patients with history of acute coronary syndromes (ACS) * Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) * Patients with left main trunk stenosis (≥50%) * Patients for whom aspirin administration is mandatory * Patients undergoing antithrombotic therapy other than aspirin * Patients with atrial fibrillation * Patients with history of stroke within six months * Patients scheduled for major surgical procedures that will require aspirin discontinuation * Patients with contraindication of aspirin * Patients expected to have a prognosis of 1 year or less due to comorbidities * Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization * Patients who are judged by attending physicians to be inappropriate to participate in this study
Conditions4
Coronary Artery DiseaseHeart DiseaseIschemic Heart DiseaseStable Angina Pectoris
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 4
SponsorTakeshi Morimoto
Started2022-06-14
Est. completion2030-03
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05347069